title: Anti-secretory and cyto-protective effects of chebulinic acid isolated from the fruits of Terminalia chebula on gastric ulcers.
abstract: In continuation of our drug discovery program on Indian medicinal plants, the gastro protective mechanism of chebulinic acid isolated from Terminalia chebula fruit was investigated. Chebulinic acid was evaluated against cold restraint (CRU), aspirin (AS), alcohol (AL) and pyloric ligation (PL) induced gastric ulcer models in rats. Potential anti-ulcer activity of chebulinic acid was observed against CRU (62.9%), AS (55.3%), AL (80.67%) and PL (66.63%) induced ulcer models. The reference drug omeprazole (10 mg/kg, p.o.) showed 77.73% protection against CRU, 58.30% against AS and 70.80% against PL model. Sucralfate, another reference drug (500 mg/kg, p.o.) showed 65.67% protection in AL induced ulcer model. Chebulinic acid significantly reduced free acidity (48.82%), total acidity (38.29%) and upregulated mucin secretion by 59.75% respectively. Further, chebulinic acid significantly inhibited H(+) K(+)-ATPase activity in vitro with IC50 of 65.01 μg/ml as compared to the IC50 value of omeprazole (30.24 μg/ml) confirming its anti-secretory activity.
authors: Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow, UP, India.
authors: Vaibhav
authors: V
authors: Mishra
authors: Manali
authors: M
authors: Agrawal
authors: Samuel Adetunji
authors: SA
authors: Onasanwo
authors: Gaurav
authors: G
authors: Madhur
authors: Preeti
authors: P
authors: Rastogi
authors: Haushila Prasad
authors: HP
authors: Pandey
authors: Gautam
authors: G
authors: Palit
authors: Tadigoppula
authors: T
authors: Narender
mesh_terms: D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001241:Aspirin; D004195:Disease Models, Animal; D000431:Ethanol; D005260:Female; D005638:Fruit; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D047348:Hydrolyzable Tannins / Q000494:pharmacology / Q000627:therapeutic use*; D020128:Inhibitory Concentration 50; D008026:Ligation; D008297:Male; D009077:Mucins / Q000378:metabolism; D009853:Omeprazole / Q000494:pharmacology / Q000627:therapeutic use; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors; D051381:Rats; D017207:Rats, Sprague-Dawley; D013270:Stomach / Q000187:drug effects*; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D013392:Sucralfate / Q000494:pharmacology / Q000627:therapeutic use; D029766:Terminalia / Q000737:chemistry*
chemical_list: D000897:Anti-Ulcer Agents; D047348:Hydrolyzable Tannins; D009077:Mucins; D010936:Plant Extracts; D054328:Proton Pump Inhibitors; C103481:chebulinic acid; D000431:Ethanol; D013392:Sucralfate; D009853:Omeprazole; D001241:Aspirin